Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2020-03-30 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the closure of the trading window for insiders due to the upcoming declaration of financial results for the quarter and year ended March 31, 2020. It mentions the trading window will open 48 hours after the financial results are declared, and that the date of the Board Meeting for declaration of results will be intimated later. The document is short (1356 characters) and serves as an announcement related to trading restrictions ahead of financial results, not the financial results themselves or a detailed report. It does not contain financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-03-30 English
Appointment
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges (National Stock Exchange of India and Bombay Stock Exchange) announcing the appointment of Dr. Vasudha V. Kamat as an Additional Independent Director of the company. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in directors and key managerial personnel. The content focuses solely on the appointment details, qualifications, and regulatory compliance disclosures related to the director's appointment. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of a change in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length is 4615 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is MANG with high confidence.
2020-03-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is extremely short (366 characters) and consists only of an address or header directed to stock exchanges (BSE Limited and National Stock Exchange of India Limited) with no substantive content, financial data, or report details. It does not contain any financial statements, management discussion, voting results, or other report content. Given the brevity and nature, it is likely a Regulatory Filing (RNS) as a general announcement or communication to exchanges without further detail.
2020-01-29 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management Discussion & Analysis for the Third Quarter FY20' and contains detailed financial data for the quarter and year-to-date periods, including revenues, expenses, and segment performance. It includes operational and financial highlights, product launches, regulatory updates, and market rankings. The presence of unaudited quarterly financial figures and comprehensive analysis indicates this is a quarterly interim report rather than a brief announcement or a full annual report. The document length is substantial (15,000 characters), and it contains substantive financial data and management commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-01-23 English
Financial Result Updates
Regulatory Filings
2020-01-23 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter from a company to the National Stock Exchange of India providing clarification on a spurt in trading volume and price of its shares. It explicitly states that there is no price sensitive information or announcement to disclose under Regulation 30 of the Listing Obligations and Disclosure Requirements. The document is a regulatory communication responding to a surveillance query, not a financial report, earnings release, or any other specific filing type. It is short (1760 characters) and serves as a regulatory filing to clarify market behavior without new financial data or report content. Therefore, it fits best under Regulatory Filings (RNS).
2020-01-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.